The high-throughput screening technology will enable the company to evaluate and screen 1000 compounds per week using various assay platform technologies
Piramal Pharma Limited’s Pharma Solutions (PPS) business, a CDMO, has reportedly made a multi-million dollar investment to create a high-throughput screening facility to augment its existing in-vitro biology capabilities at its drug discovery services site in Ahmedabad, India.
The expansion, which is expected to go live in Q3 2022, will significantly add to the primary and secondary screening capabilities of compounds prepared at the Ahmedabad site.
With integrated chemistry and biology services now available from a single site, the company says it anticipates significant improvements to drug discovery cycle times. Additional personnel with experience in biology services are also being added to the site team.
The high-throughput screening technology will enable the company to evaluate and screen 1000 compounds per week using various assay platform technologies including fluorescent imaging plate reader, TR-FRET/HTRF, and fluorescence polarisation. These platforms will be applicable to various targets (e.g., G-protein-coupled receptors (GPCRs) and kinase-targeted therapies).
Peter DeYoung, CEO, Piramal Pharma Solutions said: “Assisting customers in the discovery process is synergistic with our efforts to be a patient-centric CDMO. With this investment, we are enhancing our discovery platform by adding new in vitro biology services to our existing capabilities, making us a more integrated partner.”